In short
This article explores clinical trials using the Modified Vaccinia Ankara – Bavarian Nordic Live Virus (MVA-BN) vaccine for mpox prevention. These studies aim to assess the vaccine's effectiveness, immune response, and safety profile in adults. The trials investigate antibody production, durability of protection, and potential side effects, providing valuable insights into the use of MVA-BN as a preventive measure against mpox infection.
At a glance
- Vaccine
- Modified Vaccinia Ankara – Bavarian Nordic Live Virus (MVA-BN)
- Main Objectives
- Assess antibody production, durability of protection, and safety profile
- Study Population
- Adults aged 18 and over, eligible for MVA vaccination
- Key Measurements
- MVA-specific antibodies, neutralizing capacity, T-cell responses, adverse events
- Administration
- Subcutaneous injection, investigating full and fractional doses
- Study Duration
- Up to 48 weeks post-vaccination
- Additional Assessments
- Prevalence of STIs, incidence of mpox infection
What is Modified Vaccinia Ankara – Bavarian Nordic Live Virus (MVA-BN)?
Modified Vaccinia Ankara – Bavarian Nordic Live Virus (MVA-BN) is the active ingredient in a vaccine known by the brand name Imvanex. This vaccine is a modern, safer version of the traditional smallpox vaccine. It contains a weakened form of the vaccinia virus, which is related to but less harmful than the viruses that cause smallpox and monkeypox.
What Diseases Does MVA-BN Treat?
MVA-BN is primarily used to prevent two viral diseases:
- Smallpox: A highly contagious and often fatal disease caused by the variola virus. Although smallpox has been eradicated worldwide, the vaccine is maintained as a precautionary measure.
- Monkeypox (Mpox): A viral infection similar to smallpox but generally less severe. It can cause a painful rash, fever, and other symptoms.
How is MVA-BN Administered?
The MVA-BN vaccine is typically administered as follows:
- It is given as a suspension for injection, usually under the skin (subcutaneously).
- The standard dose is 0.5 ml.
- For initial protection, two doses are usually given, with at least 28 days between doses.
- A booster dose may be given at least one year after the second dose to maintain protection.
Effectiveness of MVA-BN
Research is ongoing to fully understand the effectiveness of MVA-BN against monkeypox. Current studies are focusing on:
- The development of MVA-specific antibodies after vaccination.
- The ability of these antibodies to neutralize the monkeypox virus in laboratory tests.
- The durability of the immune response, with antibody levels being measured up to 48 weeks after vaccination.
These studies aim to determine how well the vaccine protects against monkeypox infection and how long this protection lasts.
Safety Profile and Side Effects
MVA-BN is generally considered to have a good safety profile. However, like all vaccines, it can cause side effects. Researchers are closely monitoring:
- Local reactions at the injection site, such as redness or swelling.
- Systemic reactions like fever or fatigue.
- Any adverse events (unexpected medical problems) that occur after vaccination.
Most side effects are expected to be mild and short-lived. Serious allergic reactions are rare but possible, which is why vaccination is done under medical supervision.
Ongoing Research
Several clinical trials are currently underway to further study MVA-BN. These include:
- A study examining the long-term effectiveness of the vaccine, looking at antibody levels up to 48 weeks after vaccination.
- Research into the effectiveness of a lower-dose booster shot, which could potentially allow more people to be vaccinated with the available supply.
- Investigations into the vaccine's ability to stimulate T-cell responses, another important part of the immune system.
Who is Eligible for MVA-BN Vaccination?
Eligibility for MVA-BN vaccination may vary depending on local health guidelines. Generally, candidates include:
- Adults aged 18 years and older.
- Individuals at risk of exposure to monkeypox or smallpox.
- Those who have not previously been vaccinated against smallpox.
Some people may not be eligible, including:
- Pregnant or breastfeeding women.
- People with certain allergies or immune system disorders.
- Those who have previously had monkeypox.
Always consult with a healthcare provider to determine if MVA-BN vaccination is appropriate for you based on your individual health status and risk factors.